MSN: UC, UC Health launching clinical trial to study effectiveness of COVID-19 vaccine
Vaccine uses a genetic code to produce proteins that may generate protective antibodies
UC and UC Health are hosting a Phase 3 clinical trial to evaluate the effectiveness of a vaccine for COVID-19. UC is one of 90 sites across the United States selected for the study, which will administer the vaccine to volunteer participants and monitor its efficacy in eliciting an immune response that provides protection from COVID-19. The study is led by Carl Fichtenbaum, MD, and Maggie Powers-Fletcher, PhD, both of the UC College of Medicine Division of Infectious Diseases.
Other coverage:
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Stay up on all UC's COVID-19 stories, read more #UCtheGood content, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.
Related Stories
The Last Show with David Cooper discusses AI in education with UC’s Joshua Lambert
April 12, 2026
The Last Show with David Cooper, a global news podcast, featured Joshua Lambert, PhD, a professor and biostatistician in UC College of Nursing to discuss his latest research on using artificial intelligence for student advising.
UC enrolls first patients in clinical trial for prosthetic joint infections
April 10, 2026
The University of Cincinnati has enrolled the first patients in Peptilogics’ RETAIN clinical trial, testing an investigational drug for prosthetic joint infections after total knee replacement to reduce repeat surgeries and infection recurrence.
Long before machine guns, ancient Romans used this rapid-fire weapon
April 9, 2026
Smithsonian highlights research by UC Classics Professor Steven Ellis, who supervised archaeological work in the Porta Stabia neighborhood of Pompeii.